CSIMarket
 
Neurometrix Inc   (NURO)
Other Ticker:  
 
 
Price: $3.8600 $0.02 0.521%
Day's High: $4.135 Week Perf: -1.28 %
Day's Low: $ 3.77 30 Day Perf: 16.27 %
Volume (M): 33 52 Wk High: $ 12.40
Volume (M$): $ 127 52 Wk Avg: $6.14
Open: $3.80 52 Wk Low: $2.70



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Neurometrix Inc
NeuroMetrix Inc is a medical device company that focuses on developing and commercializing advanced technologies to aid in the diagnosis and treatment of chronic diseases, particularly those involving the nervous system. The company's flagship product is the Quell device, a wearable neurostimulation device that provides non-invasive pain relief for individuals suffering from chronic pain conditions such as neuropathy, fibromyalgia, and arthritis. In addition to pain management, Neurometrix is also engaged in the development of other medical technologies, including testing platforms and molecular biomarkers, aimed at improving patient care and outcomes. The company is headquartered in Waltham, Massachusetts and operates globally.


   Company Address: 4B Gill Street Woburn 1801 MA
   Company Phone Number: 890-9989   Stock Exchange / Ticker: NASDAQ NURO
   NURO is expected to report next financial results on March 21, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Novel Study Confirms the Accuracy of DPNCheck in Diagnosing Diabetic Peripheral Neuropathy

Published Thu, Mar 14 2024 1:00 PM UTC

presents remarkable findings from a recent publication by NeuroMetrix, Inc., announcing the successful detection of diabetic peripheral neuropathy (DPN) using DPNCheck technology. The study highlights the effectiveness of DPNCheck as a standalone method or in combination with standard electrocardiography (EKG) for accurately diagnosing DPN.Study Overview:In a groundbreaking...

Neurometrix Inc

Neurometrix Inc's Financial Nightmare: Revenue Plummets by 80% in Fourth Quarter of 2023

Neurometrix Inc, a renowned Medical Equipment & Supplies company, recently published its alarming financial report for December 31, 2023. The report reveals a devastating -80.311% decline in revenue, plummeting to a meager $0.36 million. Additionally, the company suffered a wider shortfall per share of $-1.27, in comparison to the previous financial reporting period.
Contrary to the performance of the rest of the Medical Equipment & Supplies sector, which witnessed a 6.68% revenue increase from the same period a year ago, Neurometrix Inc experienced a significant downfall. Its revenue tumbled by -69.769% to $1.20 million since the previous quarter.

Product Service News

NeuroMetrix's Strategic Review Sets Path for Neurological Innovation and Growth

Published Tue, Feb 13 2024 2:00 PM UTC

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueWOBURN, Mass., Feb. 13, 2024 - NeuroMetrix, Inc. (Nasdaq: NURO), a leading medical device company specializing in reducing the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices, has recently announced the initiation of a strategi...

Product Service News

Quell Brings Hope: NeuroMetrix's Breakthrough Trial Results Point to Promising Relief for Long COVID Sufferers

Published Tue, Dec 12 2023 2:00 PM UTC


NeuroMetrix's Quell Shows Promise in Addressing Long COVID Symptoms
NeuroMetrix, a leading medical technology company, has recently shared promising results from a pilot clinical trial involving its innovative Quell wearable neuromodulation technology. The trial focused on patients suffering from post-acute COVID-19 syndrome, commonly referred to as Long COVID. The ...

Clinical Study

NeuroMetrix Announces Exciting Findings: Quell Helps Alleviate Chemotherapy Induced Peripheral Neuropathy (CIPN) Symptoms

Published Tue, Dec 5 2023 2:02 PM UTC


NeuroMetrix, a pioneer in neurotechnology, is pleased to announce the publication of results from a Phase 2 clinical trial of Quell in the prestigious Journal of Pain. This groundbreaking study, funded by the National Institutes of Health (NIH), demonstrates that Quell effectively improves the painful symptoms associated with Chemotherapy Induced Peripheral Neuropathy (...






 

Neurometrix Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Neurometrix Inc does not provide revenue guidance.

Earnings Outlook
Neurometrix Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com